lorlatinib
- Generic Name
- lorlatinib
- Brand Names
- Lorbrena, Lorviqua
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19FN6O2
- CAS Number
- 1454846-35-5
- Unique Ingredient Identifier
- OSP71S83EU
- Background
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, fol...
- Indication
Lorlatinib is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC). In the EU, it is indicated for the treatment of adult patients with ALK-positive advanced NSCLC not previously treated with an ALK inhibitor, or whose disease has progressed after using either alectinib or ceritinib, or crizotinib and ...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06678555
- Locations
- 🇨🇳
Pfizer, Taipei, Taiwan
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT06487078
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT06410040
- Locations
- 🇨🇳
Sichuan cancer hospital, Chengdu, Sichuan, China
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
- Conditions
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Target Recruit Count
- 45
- Registration Number
- NCT06378892
- Locations
- 🇮🇹
Azienda Ospedaliera di Perugia, Perugia, Italy
🇮🇹Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Italy
🇮🇹Azienda Ospedaliero-Universitaria Careggi Oncologia Medica, Firenze, Italy
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT06361589
- Locations
- 🇨🇳
Sichuan cancer hospital, Chengdu, Sichuan, China
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06333899
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 50
- Registration Number
- NCT06282874
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Other (Non U.s.), China
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT06282991
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch, Kaohsiung City, Taiwan
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT06007937
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack, New York, United States
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
- Conditions
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Registration Number
- NCT05948462
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Messino Cancer Center, Asheville, North Carolina, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.